LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial and operating results for the third quarter ended September 30, 2015 on Thursday, November 12, 2015, prior to the market open.

Aldeyra will hold a conference call on Thursday, November 12, 2015 at 8:30 a.m. ET. Dr. Todd Brady, President and Chief Executive Officer, and Stephen Tulipano, Chief Financial Officer, will host the conference call to discuss Aldeyra's financial and operating results for the third quarter ended September 30, 2015. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13623628. A live webcast of the conference call will also be available on the investor relations page of Aldeyra's corporate website at www.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra's website for one year. In addition, a telephonic replay of the call will be available until November 19, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13623628.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

CONTACT: Corporate Contact:
         Stephen Tulipano
         Aldeyra Therapeutics, Inc.
         Tel: +1 781-761-4904 Ext. 205
         stulipano@aldeyra.com
         
         Investor Contact:
         David Burke
         The Ruth Group
         Tel: +1 646-536-7009
         dburke@theruthgroup.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.